|
Variables
|
PHA
|
EHE
|
MHP
|
IHE
|
|---|
|
No. of patients
|
11
|
15
|
3
|
13
|
|
Gender
|
|
Male
|
4 (36%)
|
2 (13%)
|
1 (33%)
|
6 (46%)
|
|
Female
|
7 (64%)
|
13 (87%)
|
2 (67%)
|
7 (54%)
|
|
Age, median, y (range)
|
52 (39–74) y
|
41 (29–69) y
|
47 (32–55)y
|
3 (0.2–24)m
|
|
Clinical symptom
|
|
Upper abdominal pain
|
4 (36%)
|
4 (27%)
|
2 (67%)
|
0
|
|
Loss of appetite and weight
|
4 (36%)
|
1 (7%)
|
0
|
0
|
|
Fever
|
1 (9%)
|
1 (7%)
|
0
|
2 (15%)
|
|
Jaundice and diarrhea
|
1 (9%)
|
0
|
0
|
3 (23%)
|
|
Growth retardation
|
0
|
0
|
0
|
1 (8%)
|
|
Thrombocytopenia
|
0
|
0
|
0
|
1 (8%)
|
|
Abdominal mass
|
0
|
0
|
0
|
6 (46%)
|
|
Asymptomatic patient
|
1 (9%)
|
3 (20%)
|
1 (33%)
|
0
|
|
Medical history
|
|
Hepatitis-B/ Cirrhosis
|
3 (27%)
|
1 (7%)
|
0
|
0
|
|
CHD
|
2 (18%)
|
1 (7%)
|
0
|
0
|
|
Hypertension
|
4 (36%)
|
3 (20%)
|
0
|
0
|
|
Diabetes
|
3 (27%)
|
3 (20%)
|
0
|
0
|
|
Treatment strategy
|
|
Hepatectomy
|
5 (45%)
|
15 (100%)
|
2 (67%)
|
13 (100%)
|
|
TACE
|
1 (9%)
|
0
|
0
|
0
|
|
Radiofrequency ablation
|
1 (9%)
|
0
|
0
|
0
|
|
Chemotherapy
|
2 (18%)
|
0
|
0
|
0
|
|
Antiangiogenic therapy
|
1 (9%)
|
0
|
0
|
0
|
|
Postoperative chemotherapy
|
1 (9%)
|
0
|
1 (33%)
|
0
|
|
Median survival time, months
|
15
|
88
|
23
|
96
|
- Note: PHA Primary hepatic angiosarcoma; EHE Epithelioid hemangioendothelioma; MHP Malignant hemangiopericytoma; IHE Infantile hemangioendothelioma; CHD Coronary heart disease; TACE Transarterial chemoembolization
